Andrew Zhu

Andrew Zhu is a hepatopancreaticobiliary oncologist at Massachusetts General Hospital who has contributed to adjuvant and neoadjuvant trials in pancreatic cancer and to understanding the limitations of CA19-9 as a surveillance biomarker. His research examines ctDNA and novel liquid biopsy approaches for post-resection monitoring in PDAC. He has led clinical trials bridging hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer management. Zhu is an active contributor to ASCO GI symposium and gastrointestinal cancer clinical guidelines.